title: Acetyl-L-carnitine in diabetic polyneuropathy: experimental and clinical data.
abstract: Diabetic polyneuropathy (DPN) is the most common late complication of diabetes mellitus. The underlying pathogenesis is multifaceted, with partly interrelated mechanisms that display a dynamic course. The mechanisms underlying DPN in type 1 and type 2 diabetes mellitus show overlaps or may differ. The differences are mainly due to insulin deficiency in type 1 diabetes which exacerbates the abnormalities caused by hyperglycaemia. Experimental DPN in rat models have identified early metabolic abnormalities with consequences for nerve conduction velocities and endoneurial blood flow. When corrected, the early functional deficits are usually normalised. On the other hand, if not corrected, they lead to abnormalities in lipid peroxidation and expression of neurotrophic factors which in turn result in axonal, nodal and paranodal degenerative changes with worsening of nerve function. As the structural changes progress, they become increasingly less amendable to metabolic interventions. In the past several years, experimental drugs--such as aldose reductase inhibitors, antioxidants and protein kinase C inhibitors--have undergone clinical trials, with disappointing outcomes. These drugs, targeting a single underlying pathogenetic factor, have in most cases been initiated at the advanced stage of DPN. In contrast, substitution of acetyl-L-carnitine (ALC) or C-peptide in type 1 DPN target a multitude of underlying mechanisms and are therefore more likely to be effective on a broader spectrum of the underlying pathogenesis. Clinical trials utilising ALC have shown beneficial effects on nerve conduction slowing, neuropathic pain, axonal degenerative changes and nerve fibre regeneration, despite relatively late initiation in the natural history of DPN. Owing to the good safety profile of ALC, early initiation of ALC therapy would be justified, with potentially greater benefits.
authors: Department of Pathology, Wayne State University and Detroit Medical Center, Detroit, Michigan 48201, USA. asima@med.wayne.edu
authors: Anders A F
authors: AA
authors: Sima
mesh_terms: D000108:Acetylcarnitine / Q000627:therapeutic use*; D000818:Animals; D003929:Diabetic Neuropathies / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D018697:Nootropic Agents / Q000627:therapeutic use*
chemical_list: D018697:Nootropic Agents; D000108:Acetylcarnitine
references: Int J Clin Pharmacol Res. 1992;12(5-6):247-52
references: 1301405
references: Diabetes Metab Res Rev. 2002 Nov-Dec;18(6):473-83
references: 12469361
references: J Peripher Nerv Syst. 1996;1(2):157-63
references: 10975724
references: J Neurosci Res. 1995 Feb 15;40(3):414-9
references: 7538169
references: Am J Physiol. 1999 Apr;276(4 Pt 2):H1223-8
references: 10199846
references: Ann Neurol. 1983 Mar;13(3):264-72
references: 6847138
references: Diabetologia. 1999 Jul;42(7):773-88
references: 10440118
references: Diabetologia. 2000 Jun;43(6):786-93
references: 10907124
references: Lancet. 1971 Feb 27;1(7696):428-30
references: 4100402
references: J Clin Invest. 1986 Feb;77(2):474-84
references: 3003160
references: Metabolism. 1995 May;44(5):677-80
references: 7752919
references: Diabetes Res Clin Pract. 2002 Jun;56(3):173-80
references: 11947964
references: Mol Pharmacol. 2002 May;61(5):989-96
references: 11961116
references: N Engl J Med. 1988 Sep 1;319(9):548-55
references: 3136331
references: J Peripher Nerv Syst. 2002 Mar;7(1):44-53
references: 11939351
references: Diabetes Care. 2005 Jan;28(1):89-94
references: 15616239
references: Ann Neurol. 1987 May;21(5):504-7
references: 2438993
references: Neuroscience. 1999 Mar;90(3):933-9
references: 10218793
references: Diabetes Care. 1992 Dec;15(12):1926-75
references: 1464246
references: Diabetes. 1997 Sep;46 Suppl 2:S82-9
references: 9285505
references: Acta Neuropathol. 1982;58(1):39-47
references: 7136515
references: Lancet. 1998 Sep 12;352(9131):837-53
references: 9742976
references: JAMA. 2000 Nov 1;284(17):2215-21
references: 11056593
references: Diabetes. 2006 Dec;55(12):3581-7
references: 17130507
references: Diabetes Care. 1999 Aug;22(8):1296-301
references: 10480774
references: Am J Physiol Endocrinol Metab. 2004 Sep;287(3):E497-505
references: 15126237
references: Drugs R D. 2002;3(4):223-31
references: 12455197
references: J Pharmacol Exp Ther. 1998 Dec;287(3):897-902
references: 9864270
references: Diabetes Care. 2001 Aug;24(8):1448-53
references: 11473085
references: Diabetes. 2002 Aug;51(8):2619-28
references: 12145179
references: J Comp Neurol. 1995 Sep 11;360(1):121-34
references: 7499558
references: Diabetes Metab Res Rev. 2005 Sep-Oct;21(5):448-58
references: 15747389
references: Brain. 2001 Nov;124(Pt 11):2319-34
references: 11673332
references: Mol Cell Biochem. 1983;57(1):3-15
references: 6358858
references: Ann Neurol. 2004 Dec;56(6):827-35
references: 15497155
references: J Neurol Sci. 2006 Sep 25;247(2):217-23
references: 16780883
references: Expert Opin Investig Drugs. 2003 Sep;12(9):1471-88
references: 12943492
references: Diabetologia. 1993 Jul;36(7):608-14
references: 8359577
references: J Clin Invest. 1988 Feb;81(2):349-64
references: 3339124
references: Diabetologia. 1997 Mar;40(3):271-81
references: 9084964
references: Diabetes Metab Rev. 1994 Oct;10(3):189-224
references: 7835170
references: Cell Mol Life Sci. 2003 Nov;60(11):2445-64
references: 14625688
references: Expert Opin Investig Drugs. 1999 Dec;8(12):2095-2119
references: 11139842
references: Diabetes. 1991 Jun;40(6):726-30
references: 1645681
references: Diabetes Metab Res Rev. 2000 Nov-Dec;16(6):408-33
references: 11114101
references: Diabetes Metab Res Rev. 2006 Jul-Aug;22(4):257-73
references: 16506271
references: J Clin Invest. 1996 Apr 15;97(8):1900-7
references: 8621774
references: Diabetes Metab Res Rev. 2007 Jan;23(1):63-70
references: 16845685
references: Muscle Nerve. 2001 Sep;24(9):1229-31
references: 11494278
references: Clin Auton Res. 2000 Feb;10 (1):13-6
references: 10750638
references: Biochem Pharmacol. 1992 Aug 4;44(3):577-85
references: 1324679
references: Neurosci Res. 1999 Mar;33(3):207-13
references: 10211764
references: Metabolism. 1996 Jul;45(7):865-72
references: 8692023
references: N Engl J Med. 1993 Sep 30;329(14 ):977-86
references: 8366922
references: Ann Neurol. 1985 Jul;18(1):21-9
references: 3898998
references: Diabetologia. 2006 Nov;49(11):2763-74
references: 17047923
references: Brain. 1999 Nov;122 ( Pt 11):2109-18
references: 10545396
references: Curr Opin Investig Drugs. 2006 Apr;7(4):324-37
references: 16625819
references: Diabetes. 2003 Feb;52(2):536-41
references: 12540632
references: J Neuropathol Exp Neurol. 2002 Oct;61(10):857-71
references: 12387452
references: Diabetes. 1999 Apr;48(4):881-9
references: 10102707
references: J Clin Invest. 1998 May 15;101(10):2036-41
references: 9593759
references: Ann N Y Acad Sci. 2006 Nov;1084:235-49
references: 17151305
references: Neuroreport. 2000 May 15;11(7):1417-20
references: 10841349
references: Diabetes. 2004 Jun;53(6):1556-63
references: 15161761
references: J Neuropathol Exp Neurol. 2002 Feb;61(2):164-75
references: 11855383
references: Acta Physiol Scand. 1981 Dec;113(4):499-506
references: 7348034
references: N Engl J Med. 1987 Mar 5;316(10):599-606
references: 3027558
references: Metabolism. 1985 Aug;34(8):721-5
references: 3927109